BPC-157
✅ Supports cellular regeneration
✅ Enhances tissue modeling
✅ Promotes fibroblast activity
✅ Stimulates angiogenic signaling
✅ Improves extracellular matrix stability
BPC-157 sisältää synteettistä peptidiyhdistettä.
✓ Lääketieteellinen tarkistus Morgan Ellis — Farmasian tutkija · 8 vuoden kokemus · Viimeisin arvio: toukokuu 2026
Quick Answer — What is BPC-157?
BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic pentadecapeptide derived from a protective gastric protein. In published preclinical research it has shown consistent effects on tendon, ligament, gut, muscle, and vascular tissue recovery via VEGF, nitric oxide, and growth-hormone-receptor signaling. Supplied in 2 mg to 10 mg lyophilized vials for laboratory research use only.
📦 Jokainen tilaus on katettuna meidän Reshipment Assurance Policy -politiikkamme piiriin — jos lähetyksesi ei saavu 20 arkipäivässä, lähetämme uuden.
| Tekniset tiedot | Yksityiskohta |
|---|---|
| CAS-numero | 137525-51-0 |
| Molekyylikaava | C62H98N16O22 |
| Molekyylipaino | 1419.55 Da |
| Sekvenssi | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) |
| Muoto | Lyofiloitu jauhe (tai toimitettu muodossa) |
| Puhdaus | ≥99 % (HPLC-varmistettu, COA saatavilla pyynnöstä) |
| Säilytys | Lyofiloitu: 2–8 °C (jääkaappi) käyttövarastoa varten; −20 °C pitkäaikaissäilytykseen avaamattomille pulloille. Uudelleenliuotettuna: 2–8 °C, käytä noin 30 päivän kuluessa. Suojaa valolta. Älä jäädytä–sulata uudelleenliuotettua liuosta. |
| Liukoisuus | Bakteriostaattinen vesi (suositus) tai steriili vesi lyhyemmille käyttöajalle |
| Tutkimuskäyttö | Vain laboratoriotutkimuskäyttöön. Ei tarkoitettu ihmis- tai eläinlääketieteelliseen diagnostiseen tai terapeuttiseen käyttöön. |
What Is BPC-157?
BPC-157 is the abbreviation of Body Protection Compound 157, a 15-amino-acid synthetic pentadecapeptide originally isolated as a fragment of a larger protective protein found in human gastric juice. Unlike most peptides it is stable in gastric acid, which has made it a frequent subject of oral-administration research in rodent models alongside the more common subcutaneous route. BPC-157 is one of the most widely studied healing-research peptides in the preclinical literature, with published work spanning tendon, ligament, gut barrier, skeletal muscle, bone, and vascular tissue.
The peptide sequence is GEPPPGKPADDAGLV, molecular weight approximately 1,419 Da, empirical formula C62H98N16O22. It is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. BPC-157 is vain laboratoriotutkimuskäyttöön and is not intended for human or veterinary diagnosis or therapy. For a deep-dive on mechanism, published trial detail, and research-dosing considerations, see our full BPC-157 -tutkimusoppaastamme.
Mechanism of Action — Three Overlapping Healing Pathways
What differentiates BPC-157 from single-pathway peptides is its simultaneous activity across three distinct signaling routes, each contributing to the observed tissue-recovery phenotype in published research:
- Angiogenesis / VEGF upregulation — BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) expression in injured tissue, promoting the formation of new capillaries. This improves local perfusion at repair sites, the rate-limiting step in tendon, ligament, and muscle healing.
- Nitric oxide (NO) pathway — BPC-157 enhances endothelial nitric oxide synthase (eNOS) activity and protects vascular endothelium against oxidative damage. In rodent models of portal hypertension, systemic vasoconstriction, and stomach ulcers, this effect is central to the compound’s protective action.
- Growth hormone receptor upregulation — BPC-157 increases growth hormone receptor (GHR) expression on fibroblasts and tenocytes, enhancing collagen type I synthesis. This mechanism is thought to underlie the observed tendon-strength gains in Achilles and medial-collateral-ligament transection models.
Because these three pathways converge on tissue that has been injured, BPC-157 produces faster and more complete recovery than single-pathway interventions in the same models. It is also notably well tolerated across the range of published doses, with minimal off-target signaling reported in toxicology research.
Julkaistut tutkimussovellukset
BPC-157 is used in laboratory research contexts that investigate:
- Tendon and ligament injury recovery — Achilles tendon transection, medial collateral ligament rupture, rotator-cuff tear rodent models (Chang et al., J Appl Physiol 2011; Staresinic et al., J Orthop Res 2003)
- Gut barrier integrity and ulcer research — gastric ulcer, colitis, and inflammatory-bowel-disease models; BPC-157’s gastric-derived origin is mechanistically relevant here (Sikiric et al., Curr Med Chem 2011)
- Skeletal muscle regeneration — post-injury recovery kinetics, myoblast proliferation, and myotube formation research
- Joint and cartilage research — osteoarthritis rodent models, cartilage matrix composition, synovial inflammation
- Vascular angiogenesis — new-capillary formation and perfusion at injured-tissue sites
- Bone healing — fracture callus formation in osteotomy and bone-defect research models
- Comparative recovery research — benchmarking against other healing peptides, especially TB-500 (Thymosin Beta-4) as the canonical systemic healing comparator. See the BPC-157 vs TB-500 -vertailu for a full side-by-side.
For broader context on where BPC-157 fits within the healing-peptide landscape, see the best peptides for muscle recovery cluster article and GHK-Cu copper peptide as a complementary anti-aging research compound. Browse the full tutkimuspeptidien luettelo liittyvistä yhdisteistä.
Saatavat vahvuudet ja pitoisuudet
MedsBase stocks BPC-157 in the following lyophilized vial sizes. Each variation ships in 10-vial, 20-vial, and 30-vial pack formats with full reconstitution guidance:
| Pullon vahvuus | Tyypillinen käyttötarkoitus | Pakkauskoot |
|---|---|---|
| 2 mg | Short research protocols, pilot dosing, titration | 10, 20 tai 30 pulloa |
| 5 mg | Vakiokoevahvuus, yleisimmin tilattu | 10, 20 tai 30 pulloa |
| 10 mg | Extended research protocols, lowest per-mg cost | 10, 20 tai 30 pulloa |
All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when researchers want to minimise injection volume in rodent protocols.
How It Compares — BPC-157 vs TB-500
BPC-157 and TB-500 are the two most-cited healing-research peptides. They are often studied in parallel because they act via complementary, largely non-overlapping mechanisms. Many preclinical protocols combine them rather than using either alone.
| Kriteeri | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Pituus | 15 amino acids (pentadecapeptide) | 43 amino acids (thymic peptide) |
| Primary mechanism | VEGF + NO + GH receptor upregulation | G-actin sequestration, cell migration |
| Distribution | More localized at injection site | Systemic, distributes widely |
| Tyypillinen tutkimusannos | 250–500 mcg, 1–2x daily | 2–2.5 mg, 2x weekly |
| Vahvin tutkimustulos | Tendon, ligament, gut barrier | Cardiac, systemic muscle, vascular |
| Yhdistäminen | Commonly co-administered with TB-500 in research | Commonly co-administered with BPC-157 in research |
For a full methodological comparison including dosing protocols and when researchers pick one over the other, read BPC-157 vs TB-500: which healing peptide for your recovery goal.
Säilytys ja liuotus
Ennen liuotusta: store lyophilized vials refrigerated at 2–8 °C in original packaging. Lyophilized BPC-157 is stable under these conditions for up to 36 months. Avoid freeze-thaw cycles on the powder.
Uudelleenliuotusmenettely: inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake) per the dilution table above. Swirl gently — do ei ravistele — ja anna 2–5 minuuttia täydelliseen liukenemiseen. Oikein uudelleenliuotettu liuos tulisi olla kirkas ja väritön.
Uudelleenliuotuksen jälkeen: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration.
Usein Kysytyt Kysymykset
What is BPC-157 used for in research?
BPC-157 is used in laboratory research investigating tendon and ligament healing, gut barrier integrity, skeletal muscle recovery, vascular angiogenesis, anti-inflammatory signaling, and bone healing. It is ei FDA-approved and is sold here strictly for laboratory research use only.
How is BPC-157 different from TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric juice, acting mostly locally via VEGF, nitric oxide, and growth-hormone-receptor pathways. TB-500 is a 43-amino-acid thymic peptide that acts systemically via G-actin binding and cell migration. The two are often co-administered in research because their mechanisms are complementary rather than overlapping.
What is the typical BPC-157 research dose?
Published preclinical protocols typically use 250–500 mcg per administration, given once or twice daily for 4–8 week cycles. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — 10 ticks on a U-100 syringe equals 250 mcg.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA, EMA, MHRA, or any other regulator for human therapeutic use. All BPC-157 sold by research-use-only suppliers is for laboratory investigation and should not be administered to humans.
How should BPC-157 be stored?
Liofilisoidut pullot: jääkaapissa 2–8 °C alkuperäisessä pakkauksessa, säilyvyys jopa 36 kuukautta. Rekonstituoitu liuos: jääkaapissa 2–8 °C, käytä 30 päivän kuluessa. Älä jäädytä rekonstituoitua liuosta — jäätymis- ja sulamissyklit heikentävät peptidin laatua.
How do I reconstitute BPC-157?
Follow the reconstitution reference chart above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 2–5 minutes for full dissolution. Do ei shake the vial.
Mitä vahvuuksia MedsBase pitää varastossaan?
MedsBase carries BPC-157 in 2 mg, 5 mg, and 10 mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.
Can BPC-157 and TB-500 be stacked in research?
Yes. BPC-157 and TB-500 are frequently co-administered in preclinical research because their mechanisms are complementary. BPC-157 acts mostly locally via growth-factor upregulation; TB-500 acts systemically via G-actin binding and cell migration. Combined protocols are described in our comparison guide.
Does BPC-157 cause side effects in research?
Published preclinical research across rodent species has reported a notably clean safety profile at typical research doses, with no consistent off-target signals and good tolerability. Long-term human safety data are not available because human trials have not been completed.
What is the difference between oral and injectable BPC-157 in research?
BPC-157 is unusually stable in gastric acid due to its gastric-juice-derived origin, so oral administration is feasible in rodent protocols (unlike most peptides). Subcutaneous injection remains the most common research route in the literature because it produces more reproducible plasma concentrations.
What is the half-life of BPC-157?
In preclinical research, BPC-157 has an estimated plasma half-life of approximately 4 hours following subcutaneous administration. Oral route studies in rodent models suggest shorter systemic clearance but sustained local effects within the gastrointestinal tract, attributed to the peptide’s unusual acid-stability.
How long does BPC-157 take to show effects in preclinical research?
Most preclinical studies using BPC-157 in tendon, ligament, and gut injury models report measurable tissue-level changes within 7–14 days. The time-course varies with the research model, injury severity, route of administration, and dose used in the study design.
Can I order BPC-157 for international shipping?
Yes. MedsBase ships BPC-157 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking.
BPC-157 protocols for tendon, ligament, and soft-tissue recovery typically pair it with TB-500 for synergistic angiogenic + cytoskeletal effects; for the bundled regimen see our Peptide Healing Stack (BPC-157 5 mg + TB-500 5 mg + bakteriostaattinen vesi) with both lyophilised vials and reconstitution water in one parcel at $0 peptide-shipping rate.
Muut peptidit toipumis- ja suorituskykytutkimukseen
- TB-500 — Thymosin Beta-4 fragmentti — pehmytkudosten ja verisuonten toipumistutkimus
- Ipamorelin — Selektiivinen ghreliniagonisti — puhdas GH-pulssi ilman kortisolia/prolaktiinia
- CJC-1295 DAC:lla — GHRH-analogia pidennettyä puoliintumisaikaa
- GHK-Cu — Kuparipeptidi — ihon ja sidekudosten uusiutumistutkimus
- IGF-1 LR3 — Long-R3 IGF-1 analog — anabolic / regenerative research
Lisälukemista
📖 Lue tutkimus tämän peptidin taustalla
Lue kattava näyttöön perustuva oppaamme: BPC-157 — mechanism, trial data & outlook. Kattaa vaikutusmekanismin, julkaistut tutkimustiedot, tyypilliset tutkimusannosvälit, rekonstituointiohjeet, yhdistelmäkäytön harkinnat sekä turvallisuus/kelpoisuusrajoitukset.
Lisää vaihtoehtoja Peptideissä
Luokiteltu MedsBase-tilausmäärän mukaan — mitä muut asiakkaat tässä kategoriassa valitsevat.
| Vahvuus | 2 mg, 5 mg, 10 mg |
|---|---|
| Määrä | 10 pulloa, 20 pulloa, 30 pulloa |
BPC-157
Kysymykset ja vastaukset
BPC-157
Liittyvät tuotteet
Arvostelut
Ei vielä arvosteluja